June 17, 2019 / 10:10 AM / a month ago

VBI hepatitis B vaccine meets main goals in late-stage trial

June 17 (Reuters) - VBI Vaccines Inc said on Monday a late-stage study testing its hepatitis B vaccine met its main goals.

The trial tested VBI’s Sci-B-Vac against GlaxoSmithKline’s ‘s Engerix-B vaccine, which was first approved in the United States in 1989. (Reporting by Tamara Mathias in Bengaluru; Editing by Shailesh Kuber)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below